Previous close | 22.90 |
Open | 22.90 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 22.90 - 22.90 |
52-week range | 21.22 - 36.25 |
Volume | |
Avg. volume | 846 |
Market cap | 12.301B |
Beta (5Y monthly) | 0.26 |
PE ratio (TTM) | 33.38 |
EPS (TTM) | 0.69 |
Earnings date | N/A |
Forward dividend & yield | 0.42 (1.77%) |
Ex-dividend date | 29 Dec 2022 |
1y target est | N/A |
SAN DIEGO & TOKYO, July 18, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced publication of data from the Phase 1b clinical study of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor, in
SAN DIEGO & TOKYO, June 10, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that data from the zandelisib clinical development program, including the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered
SAN DIEGO & TOKYO, June 04, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced data from the ongoing Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta